Articles by Keyword for

Dr. Gracer reviews cutting edge pharmaceutical, nutritional, and emotional approaches to dealing with addictions to alcohol and drugs. The strategies presented are a breakthrough to a new level of excellence in treating addictions.                  

Whenever a new technology is invented, if it is good it will displace the old. This can have profound economic consequences that are abhorent to business-minded corporations. Conflicts of interest with the FDA are discussed.

  Lithocholic acid (LCA) is a liver bile acid that has the ability to selectively kill cancer cells while not affecting normal cells. It works by causing cancer cell mitochondria to self-destruct. LCA also activates the vitamin D receptor site. It prevents whole tumor growth and slows down the development of metastases. In tests it has been shown to...

How we move reflects us physically, emotionally, and spiritually. It reveals how we relate to life. There are even social aspects of how it is okay to move, especially in natural movements of the hips.              

Every year there are advances in research that should be brought forward into clinical practice but don't make it because of conflicts of interest. One reason is that new technologies may require more study or financial investment by the practitioner. Second, new technologies will replace old ones that are profitable. The example of the photon stimulator...

  Gary tells the story of his journey through his own failed personal relationships and what it took to find a relationship that works. He attributes his success to being authentic and knowing the purpose of his marriage.

The first step in considering treatment is to make an accurate diagnosis. The body heals itself and we need to support it to promote healing by looking at a wide range of therapies that range from nutrition to surgery. Lifestyle medicine is the first place to start. Having flexibility in choosing a treatment is key to finding the best treatment.  New...

  Pradaxa is currently the only FDA approved drug that inhibits factor Xa and seems to have significant advantages over Coumadin. Early studies have shown a 21% less likely risk of stroke in atrial fibrillation, a 31% lower risk of bleeding, and an 11% lower mortality rate. Two drugs under study by the FDA now include Xarelto, and Eliquis.  If...